FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHAN	GES IN BE	ENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) (C/O WE) 1030 MA	C/O WEREWOLF THERAPEUTICS, INC. 1030 MASSACHUSETTS AVENUE, SUITE 210  (Street) CAMBRIDGE MA 02138				2. Issuer Name and Ticker or Trading Symbol Werewolf Therapeutics, Inc. [ HOWL ]  3. Date of Earliest Transaction (Month/Day/Year) 08/03/2020  4. If Amendment, Date of Original Filed (Month/Day/Year)						6. li	S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director					
	(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Transa Date (Month/D			ansactio	action 2A. Deemed Execution Date,		3. Transacti Code (Ins	4. Securi Dispose	urities Acquired (A) o ed Of (D) (Instr. 3, 4 a		5. Amount of		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	(e.g. 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa	5. Number of Derivative Securities		6, Options, convertil 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Stock Option (right to buy)	\$1.56	08/03/2020		A		145,531		(1)	08/02/2030	Common Stock	145,531	\$0.00	145,53:	1	D		
Stock Option (right to buy)	\$4.77	12/08/2020		A		118,781		(2)	12/07/2030	Common Stock	118,781	\$0.00	118,78	1	D		
Stock Option (right to buy)	\$16	04/30/2021		A		48,455		(3)	04/29/2031	Common Stock	48,455	\$0.00	48,455	5	D		

## **Explanation of Responses:**

- 1. The option was granted on August 3, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.
- 2. The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.
- 3. The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025.

## Remarks:

/s/ Reid Leonard, Attorney-in-<u>fact</u>

05/04/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.